Introduction and objective. Receiving a cancer diagnosis can lead to significant mental distress, highlighting the necessity for comprehensive medical care that includes psychological support. Effective psycho-oncological therapy can help patients find fulfillment regardless of their prognosis, while also improving overall outcomes and treatment adherence. This article aims to review the medical literature on the mental health challenges faced by cancer patients and to explore potential treatment modalities. Review methods. Implementing Google Scholar and PubMed, a literature analysis was conducted, with particular attention paid to terms like "psychooncology," "anxiety," "depression," "cancer," "grief," and "PTSD." The period of consideration for articles was from 2017 to 2024. Brief description of the state of knowledge. Grief, anxiety, PTSD, despair, and other mental health problems can arise after receiving a cancer diagnosis. In order to improve treatment adherence and survival rates, psychological well-being must be addressed. Empirical evidence indicates that psychological disorders can hinder adherence to therapy and elevate the risk of death from cancer. Furthermore, as families often endure significant stress throughout the disease, psychological care is beneficial to both patients and their relatives. It is possible to enhance adherence and reduce symptoms by using an integrated strategy that takes into consideration both physical and mental health. Conclusions. An essential part of holistic cancer care is psycho-oncology, which enhances patients' general health and quality of life. Psycho-oncological therapy must be incorporated into standard cancer care in order to improve treatment outcomes and assist patients in overcoming their condition.
6 February 2025 in Journal of Pre-Clinical and Clinical Research
Introduction and objective: Male androgenic alopecia (AGA), is an age-related, genetic, progressive condition affecting more than half of the male population over the age of fifty. 5-alpha reductase inhibitors combined with minoxidil, commonly used in AGA therapy, are associated with potential...
20 February 2025 in Health Problems of Civilization
Psylocybina to psychoaktywny związek chemiczny występujący w grzybach z rodzaju Psilocybe, które zyskały znaczną popularność w ostatniej dekadzie ze względu na ich wpływ na neuroplastyczność, działanie serotoninergiczne oraz zdolność do tworzenia nowych połączeń między obszarami, które komunikowały się wcześniej ze sobą. Celem niniejszego badania jest ocena potencjalnych zastosowań psylocybiny w leczeniu chorób psychicznych. Do opracowania artykułu wykorzystano bazy danych „PubMed” i „Google Scholar”, ze szczególnym uwzględnieniem artykułów opublikowanych po 2021 roku. Psylocybina jest uważana za alternatywną opcję terapeutyczną dla zaburzeń psychicznych. Według niektórych badań już pojedyncza dawka lub kilka małych dawek, w połączeniu z psychoterapią (PAP, psychedelic- associated psychotherapy), może przynieść szybkie korzyści, które mogą utrzymywać się przez wiele miesięcy. Psylocybina stanowi obiecującą alternatywę dla pacjentów, u których standardowe leczenie nie przyniosło oczekiwanych rezultatów, którzy zmagają się z efektami ubocznymi lub nie odpowiada im forma tradycyjnego leczenia. Badania podkreślają skuteczność PAP w leczeniu pacjentów z depresją, lękiem, uzależnieniami, PTSD i OCD, anoreksją. Psylocybina wykazuje najlepszy profil bezpieczeństwa pośród innych psychodelików. Nie powoduje działań niepożądanych zagrażających życiu i zdrowiu, a przeciwwskazania do jej stosowania są nieliczne. Jednakże czasami może ujawniać zaburzenia psychotyczne. Potrzeba, więcej badań naukowych, które wykazałyby standard leczenia psylocybiną, i tym samym pozwoliły na wprowadzenie halucynogenów do codzienności pacjentów.
20 October 2024 in Journal of Education, Health and Sport
CRC occupies one of the leading positions among gastrointestinal malignancies and is a significant problem in Europe since it is the third most frequently diagnosed cancer. Recent developments in diagnostic techniques have led to higher chances of early diagnosis and survival; nevertheless, CRC is highly likely to relapse in the survivorably younger individuals. The importance of the current chemotherapy treatment and potential key therapeutic targets are identified in this review so that the molecular alterations causing drug resistance in CRC can be studied.Current literature formed the basis of this review by reviewing the molecular processes that underlie CRC, with emphasis on the mutational alterations in genes such as SENP1, KRAS, APC, TP53, and BRAF that play critical roles in CRC and resistance to treatment. Chemotherapy for CRC, targeting therapies, and immuno therapies have been discussed particularly with reference to their effectiveness for treatment and overcoming resistance.Genomic alterations in some important genes are involved in the onset of CRC and also determined the response to therapies. The KRAS mutations are associated with the resistance to EGFR inhibitors; however, BRAF mutations require BRAF/MEK inhibitors. Lack of MMR system SSR as a trigger for MSI-H status suggests a better response to immunotherapies. In addition, new molecules including SENP1, which involved the DNA repair pathway, and combination using CDK4/6 inhibitors are currently under development to overcome resistance and enhance the patients’ benefits.Colorectal cancer is still a problem, primarily because of its genetic character and high rates of recurrence. Even though chemotherapy and targeted therapies offer helpful results, the problem of resistance stands in the way. Subsequent studies should aim at symptomatic treatment outcomes and combine different drugs in order to enhance long-term treatment outcomes.
9 October 2024 in Journal of Education, Health and Sport
Introduction and purpose: Alopecia Areata (AA) is an inflammatory autoimmune disorder characterized by non-scarring hair loss. While it is not life-threatening, it can lead to significant psychological distress. With advancements in modern medicine, new treatments, personalized therapies, and various therapeutic options have emerged. The aim of this study is to review and assess the efficacy, outcomes, and side effects of the available treatment options. Material and methods : To compile this article “PUBMED” and “Google Scholar” databases were used with the great attention given to the articles not older than the year 2018 Brief description of the state of knowledge: There are various treatment options for Alopecia Areata (AA), beginning with topical treatments such as corticosteroids, prostaglandin analogs, minoxidil, and contact immunotherapy. In more severe cases, systemic therapy, biological therapy, or alternative treatments should be considered. Results and conclusions: In the treatment of mild Alopecia Areata (AA), topical therapies are the preferred option due to their minimal side effects and easy to apply nature, with corticosteroids demonstrating the best outcomes, particularly when used in combination therapies. In patients with moderate or severe AA, systemic therapies are recommended, alone or in combination with topical treatment. In patients resistant to other forms of therapy, biological treatments or less commonly used methods should be considered.
Among gastrointestinal disorders, to this day, many diseases are insufficiently studied. One of these under-researched conditions is eosinophilic gastroenteritis. The underlying cause of this rare disease is an inflammatory process affecting a large section of the alimentary tract – mainly the stomach and small intestine. This condition presents with non-specific clinical symptoms. Due to similarities between the initial symptoms and those of other prevalent gastrointestinal conditions, patients often initially receive an inaccurate diagnosis, leading to ineffective treatment and a significant challenge for physicians. Unfortunately, even if the diagnosis is made, the treatment process remains challenging. Due to the lack of precise recommendations regarding the medical approach, some individuals need to modify their therapy multiple times before the symptoms resolve. This systematic review is based on the PubMed database and concentrates on articles published between 2014 and 2024, focusing on case reports of patients under 18 years of age. The main aim was to expand the knowledge regarding the etiology, symptoms, diagnostic methods, and treatment approaches for eosinophilic gastroenteritis .